Details: pack, label wording, sources, registration
Atropine-Darnitsa 1 mg/ml (0.1%), Solution
1 ml ampoule, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Haemodynamically important vagal bradycardia; one early dose in selected nonshockable CPR; or titrated control of muscarinic organophosphate/carbamate signs. Not routine premedication or treatment of nicotinic paralysis.
6.8/10
Situational / acceptable
Details →
vetman assessment
Atropine-Darnitsa
×
1 mg/ml (0.1%), 1 ml ampoule, solution for injection, human medicine
Assessed clinical scope Dog · Haemodynamically important vagal bradycardia; one early dose in selected nonshockable CPR; or titrated control of muscarinic organophosphate/carbamate signs. Not routine premedication or treatment of nicotinic paralysis. · IV,IM,SC
Care setting Emergency, anaesthesia or toxicology care with ECG, perfusion, temperature, respiratory and antimuscarinic-endpoint monitoring; route selected for urgency and clinical context
vetman score
6.8/10
Situational / acceptable
Evidence confidence: High
Georgia: Yes, human · № რ-046155 · Verified on 16 Oct 2026
Off-label use
A clinically valuable emergency antimuscarinic when the exact indication is defined: significant vagal bradycardia, one selected early CPR dose, or muscarinic poisoning signs. The product is not a routine premedication or universal arrest drug. Separate the low bradycardia dose from poisoning titration, monitor ECG/perfusion and treat ventilation, nicotinic weakness and exposure control independently.
Regulatory and scientific credibility 7.0/10
The exact Darnitsa 1 mg/ml ampoule has a current sourced Georgian human authorisation and an official exact manufacturer instruction, but the exact brand is not authorised in the checked EU/EEA, GB or US registers. A separate EU-authorised 1 mg/ml veterinary injection supports formulation/route applicability, while this human product remains off-label.
Clinical efficacy 8.0/10
Atropine is an established antimuscarinic with a current EU-authorised canine injectable comparator. RECOVER recommends it for haemodynamically compromising bradycardia and allows one early dose in selected nonshockable CPR, but CPR outcome evidence is low and high-vagal benefit is expert opinion. A 102-dog poisoning cohort and toxicology guidance support control of muscarinic signs; atropine neither reverses nicotinic weakness nor replaces ventilation, decontamination or an oxime when indicated.
Safety and tolerability 6.0/10
Atropine has a narrow indication-dependent margin rather than a generally benign profile: excessive or repeated dosing can cause tachycardia/tachyarrhythmia, reduced cardiac output, hyperthermia, ileus, urinary retention, thickened airway secretions, mydriasis/glaucoma aggravation and central excitation. ECG, perfusion and clinical endpoints make short monitored emergency use manageable; obstruction, glaucoma and pre-existing tachyarrhythmia require particular caution.
Clinical practicality 6.0/10
The 1 mg/ml single-use 1 ml ampoule is familiar, needs no reconstitution and supports accurate IV/IM/SC withdrawal for many dogs. Small bradycardia doses still need a finely graduated syringe, while severe poisoning can require repeated multi-ampoule dosing and substantial stock because the titrated dose may be tens of times higher; opened remainder is discarded.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use with known atropine hypersensitivity. Avoid or obtain specialist justification in uncontrolled tachyarrhythmia, mechanical gastrointestinal or urinary obstruction, paralytic ileus and angle-closure glaucoma; atropine can worsen each through antimuscarinic effects. Never merge the indications into one dose range. Bradycardia/CPR dosing is around 0.04 mg/kg, whereas organophosphate/carbamate treatment is titrated over a much higher 0.2–2 mg/kg range; selecting the poisoning dose for bradycardia can cause severe toxicity. Use ECG, heart rate, pulse quality and blood pressure before and after dosing. Stop automatic redosing and reassess for excessive tachycardia, ventricular ectopy, worsening perfusion, agitation, hyperthermia or absent clinical benefit; atropine can raise rate while reducing useful filling/output. In organophosphate/carbamate poisoning atropine treats muscarinic secretions, bronchoconstriction and bradycardia but does not reverse nicotinic fasciculation, weakness or respiratory paralysis. Secure ventilation and supportive care, decontaminate safely and use an oxime when indicated; do not titrate only to pupil dilation. For poisoning, titrate to clinically meaningful drying of bronchial/oral secretions, improved ventilation and adequate heart rate/perfusion, then reassess frequently. Response can diminish with repeated treatment; avoid reflex dosing on a fixed schedule when muscarinic endpoints are already controlled. During CPR, high-quality BLS, rhythm diagnosis, ventilation, defibrillation and indicated vasopressors take priority. RECOVER permits one early atropine dose for selected nonshockable arrest/high vagal tone and recommends against repeated doses; evidence for survival benefit is low. Additive antimuscarinic toxicity can occur with other anticholinergics, some antihistamines, tricyclic antidepressants and phenothiazines. Review anaesthetic and emergency drugs, and distinguish atropine-responsive vagal bradycardia from hypoxia, electrolyte disturbance, hypothermia, drug overdose or structural conduction disease. Monitor temperature, hydration, gut sounds, urine output and airway secretions after clinically important or repeated exposure. Antimuscarinic drying can thicken respiratory secretions; hyperthermia risk rises in hot environments and patients with impaired heat dissipation. The 1 mg/ml concentration can produce very small bradycardia volumes in cats and small dogs. Use a verified concentration, patient weight and finely graduated syringe or a pharmacy-approved dilution; never confuse mg with ml or atropine sulfate with a differently expressed base-equivalent strength. Reproductive safety of these exact human ampoules in pregnant or lactating bitches/queens is not established. In a life-threatening emergency use the minimum effective dose after benefit-risk assessment; for elective premedication, choose an indication-specific alternative rather than assuming routine benefit. Assessment sources +
Close
Cat
Haemodynamically important vagal bradycardia; one early dose in selected nonshockable CPR; or titrated control of muscarinic organophosphate/carbamate signs. Not routine premedication or treatment of nicotinic paralysis.
6.9/10
Situational / acceptable
Details →
vetman assessment
Atropine-Darnitsa
×
1 mg/ml (0.1%), 1 ml ampoule, solution for injection, human medicine
Assessed clinical scope Cat · Haemodynamically important vagal bradycardia; one early dose in selected nonshockable CPR; or titrated control of muscarinic organophosphate/carbamate signs. Not routine premedication or treatment of nicotinic paralysis. · IV,IM,SC
Care setting Emergency, anaesthesia or toxicology care with ECG, perfusion, temperature, respiratory and antimuscarinic-endpoint monitoring; route selected for urgency and clinical context
vetman score
6.9/10
Situational / acceptable
Evidence confidence: High
Georgia: Yes, human · № რ-046155 · Verified on 16 Oct 2026
Off-label use
A useful feline emergency antimuscarinic for significant vagal bradycardia, one selected early CPR dose or muscarinic poisoning signs, with an authorised veterinary comparator and feline toxicosis evidence. Benefit depends on correct indication and titration: protect against tiny-volume error, monitor ECG/temperature/GI-urinary function and do not mistake drying secretions for treatment of nicotinic paralysis.
Regulatory and scientific credibility 7.0/10
The exact Darnitsa 1 mg/ml ampoule has a current sourced Georgian human authorisation and an official exact manufacturer instruction, but the exact brand is not authorised in the checked EU/EEA, GB or US registers. A separate EU-authorised 1 mg/ml veterinary injection supports formulation/route applicability, while this human product remains off-label.
Clinical efficacy 7.5/10
Atropine has a current EU-authorised feline injectable comparator and RECOVER support for haemodynamically compromising bradycardia and one selected early CPR dose, although outcome evidence is low. A 39-cat poisoning cohort and a successful severe-toxicosis CRI case support muscarinic control but do not establish comparative efficacy. It does not reverse nicotinic weakness or replace ventilation, decontamination or an oxime.
Safety and tolerability 6.0/10
Atropine has a narrow indication-dependent margin rather than a generally benign profile: excessive or repeated dosing can cause tachycardia/tachyarrhythmia, reduced cardiac output, hyperthermia, ileus, urinary retention, thickened airway secretions, mydriasis/glaucoma aggravation and central excitation. ECG, perfusion and clinical endpoints make short monitored emergency use manageable; obstruction, glaucoma and pre-existing tachyarrhythmia require particular caution.
Clinical practicality 7.0/10
The 1 mg/ml single-use 1 ml ampoule is ready to use and usually supplies enough drug for feline bradycardia or initial poisoning management. A small cat at the low bradycardia range may require only a few hundredths of a millilitre, demanding a finely graduated syringe or validated dilution; repeated toxicosis dosing still needs close endpoint monitoring and opened remainder is discarded.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use with known atropine hypersensitivity. Avoid or obtain specialist justification in uncontrolled tachyarrhythmia, mechanical gastrointestinal or urinary obstruction, paralytic ileus and angle-closure glaucoma; atropine can worsen each through antimuscarinic effects. Never merge the indications into one dose range. Bradycardia/CPR dosing is around 0.04 mg/kg, whereas organophosphate/carbamate treatment is titrated over a much higher 0.2–2 mg/kg range; selecting the poisoning dose for bradycardia can cause severe toxicity. Use ECG, heart rate, pulse quality and blood pressure before and after dosing. Stop automatic redosing and reassess for excessive tachycardia, ventricular ectopy, worsening perfusion, agitation, hyperthermia or absent clinical benefit; atropine can raise rate while reducing useful filling/output. In organophosphate/carbamate poisoning atropine treats muscarinic secretions, bronchoconstriction and bradycardia but does not reverse nicotinic fasciculation, weakness or respiratory paralysis. Secure ventilation and supportive care, decontaminate safely and use an oxime when indicated; do not titrate only to pupil dilation. For poisoning, titrate to clinically meaningful drying of bronchial/oral secretions, improved ventilation and adequate heart rate/perfusion, then reassess frequently. Response can diminish with repeated treatment; avoid reflex dosing on a fixed schedule when muscarinic endpoints are already controlled. During CPR, high-quality BLS, rhythm diagnosis, ventilation, defibrillation and indicated vasopressors take priority. RECOVER permits one early atropine dose for selected nonshockable arrest/high vagal tone and recommends against repeated doses; evidence for survival benefit is low. Additive antimuscarinic toxicity can occur with other anticholinergics, some antihistamines, tricyclic antidepressants and phenothiazines. Review anaesthetic and emergency drugs, and distinguish atropine-responsive vagal bradycardia from hypoxia, electrolyte disturbance, hypothermia, drug overdose or structural conduction disease. Monitor temperature, hydration, gut sounds, urine output and airway secretions after clinically important or repeated exposure. Antimuscarinic drying can thicken respiratory secretions; hyperthermia risk rises in hot environments and patients with impaired heat dissipation. The 1 mg/ml concentration can produce very small bradycardia volumes in cats and small dogs. Use a verified concentration, patient weight and finely graduated syringe or a pharmacy-approved dilution; never confuse mg with ml or atropine sulfate with a differently expressed base-equivalent strength. Reproductive safety of these exact human ampoules in pregnant or lactating bitches/queens is not established. In a life-threatening emergency use the minimum effective dose after benefit-risk assessment; for elective premedication, choose an indication-specific alternative rather than assuming routine benefit. Assessment sources +
Close
Administration route
Intravenous, Intramuscular, Subcutaneous
Registration
Georgia
Yes, human
In force until 13 Aug 2031
Human (Ministry of Health, RAMA)
In the register: ატროპინი-დარნიცა 1 მგ/მლ (0.1%), 1 მლ ამპულა, საინექციო ხსნარი
№ რ-046155
Verified on: 16 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
